Clinical Trials Browser

Phase 2 × Active not recruiting × cemiplimab × Clear all

NCT06855212 2026-05-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05574101 2026-05-15

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Phase 2 Active not recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Phase 2 Active not recruiting

Multiple Myeloma

NCT05694871 2026-05-11

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Phase 2 Active not recruiting

Liposarcoma

NCT05557591 2026-05-06

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Phase 2 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT05961709 2026-05-04

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT05553834 2026-04-13

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT05401786 2026-03-12

RAD-IO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Phase 2 Active not recruiting

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Phase 2 Active not recruiting

Melanoma, Skin Neoplasms

NCT06161441 2026-01-12

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Phase 2 Active not recruiting

Resectable Non-small Cell Lung Cancer

NCT04315701 2025-11-20

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Phase 2 Active not recruiting

Skin Neoplasms

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

Invasive Breast Cancer

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT04050436 2025-01-27

CERPASS

Phase 2 Active not recruiting

Carcinoma, Carcinoma, Squamous Cell

NCT05878288 2024-11-21

DISCERN

Phase 2 Active not recruiting

Neoplasms

NCT04679480 2024-07-30

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Phase 2 Active not recruiting

Carcinoma, Basal Cell